NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
1. NuCana will present at ESMO Congress 2025 in Berlin. 2. Presentation on NUC-7738's synergy with PD-1 inhibition for renal cancer. 3. Abstract published in the ESMO Abstract Book on October 13, 2025. 4. NUC-7738 is in Phase 2 trials for advanced solid tumors. 5. NuCana's ProTide technology aims to improve cancer treatment efficacy.